855291-54-2
855291-54-2
Chemical Structure
ABT-107
- CAS No.: 855291-54-2
- Formula:C19H20N4O
- Molecular Weight:320.39
IUPAC Name: (R)-3-((6-(1H-indol-5-yl)pyridazin-3-yl)oxy)quinuclidine
InChIKey: LUKNJAQKVPBDSC-SFHVURJKSA-N
SMILES: [C@H]1(C2CCN(CC2)C1)OC3=CC=C(C4=CC=C(NC=C5)C5=C4)N=N3
Biological Activity: ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ABT-107 | 99.73% | ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. R Scott Bitner, et al. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. [Content Brief]
- [2]. Tanuja Bordia, et al. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp Neurol. 2015 Jan;263:277-84. [Content Brief]
